Alpha Tau Medical (DRTS) EBIT (2021 - 2026)

Alpha Tau Medical has disclosed EBIT across 6 years of filings, most recently posting $13.3 million for Q1 2026.

• EBIT for Q1 2026 came in at $13.3 million, up 43.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.3 million (up 25.37% YoY), and the FY2025 annual result was $42.3 million, up 17.33% from the prior year.
• EBIT came in at $13.3 million for Q1 2026 at Alpha Tau Medical, up from $12.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $13.3 million in Q1 2026 to a low of $7.4 million in Q3 2022.
• The 5-year median for EBIT is $8.9 million (2023), against an average of $9.4 million.
• Across the five-year window, EBIT surged 221.06% in 2022 and fell 7.11% in 2024, its largest moves.
• Alpha Tau Medical's EBIT stood at $8.0 million in 2022, then advanced by 24.52% to $9.9 million in 2023, then rose by 3.33% to $10.3 million in 2024, then climbed by 22.66% to $12.6 million in 2025, then gained by 5.64% to $13.3 million in 2026.
• The last three EBIT figures came in at $13.3 million (Q1 2026), $12.6 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.